Advisors Capital Management LLC Raises Stock Position in Medtronic PLC $MDT

Advisors Capital Management LLC lifted its holdings in shares of Medtronic PLC (NYSE:MDT) by 2.9% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 435,376 shares of the medical technology company’s stock after purchasing an additional 12,394 shares during the quarter. Advisors Capital Management LLC’s holdings in Medtronic were worth $41,465,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in the business. Brighton Jones LLC lifted its holdings in Medtronic by 1,368.0% during the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after buying an additional 37,265 shares in the last quarter. Sivia Capital Partners LLC raised its stake in shares of Medtronic by 9.6% in the second quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock valued at $380,000 after acquiring an additional 381 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Medtronic in the second quarter valued at $10,286,000. Chicago Partners Investment Group LLC boosted its holdings in Medtronic by 17.6% in the second quarter. Chicago Partners Investment Group LLC now owns 8,194 shares of the medical technology company’s stock valued at $754,000 after purchasing an additional 1,224 shares during the period. Finally, Lyell Wealth Management LP acquired a new position in Medtronic during the 2nd quarter worth $893,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Stock Down 3.2%

Shares of NYSE:MDT opened at $96.33 on Wednesday. The firm has a 50 day simple moving average of $99.19 and a 200-day simple moving average of $96.58. Medtronic PLC has a twelve month low of $79.55 and a twelve month high of $106.33. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $123.50 billion, a PE ratio of 25.96, a P/E/G ratio of 2.62 and a beta of 0.71.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.34 by $0.02. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The firm had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. During the same period last year, the business earned $1.38 EPS. Medtronic’s revenue for the quarter was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities analysts predict that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were given a dividend of $0.71 per share. The ex-dividend date was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.9%. Medtronic’s payout ratio is 76.55%.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Q3 beat — Medtronic exceeded consensus on revenue (~$9.02B) and adjusted EPS ($1.36), driven by robust demand for heart devices and diabetes monitors, supporting the bullish growth story. Medtronic beats quarterly profit estimates on robust demand for heart devices
• Positive Sentiment: Strong segment performance — Cardiovascular (including cardiac ablation/PFA) and Diabetes delivered outsized growth (cardiac ablation growth cited very strong), making this one of the company’s best quarters in recent years and underpinning revenue momentum. Medtronic reports strong third quarter fiscal 2026 results with highest enterprise revenue growth in 10 quarters
• Positive Sentiment: Regulatory/product wins — FDA clearance and immediate commercial activity for the Hugo™ robotic system (first U.S. case performed) and clearances for other surgical/spine systems expand addressable markets and could accelerate procedure volumes. Medtronic announces first surgery with Hugo™ robotic-assisted surgery system in the U.S. performed at Cleveland Clinic
• Positive Sentiment: Additional approvals and pipeline progress — FDA nod for Infuse bone graft in TLIF procedures and MiniMed Flex submission keep product catalysts on the calendar for surgical and diabetes franchises. Medtronic gets FDA nod for Infuse bone graft in TLIF procedures
• Neutral Sentiment: Guidance reiterated — Management reaffirmed FY26 organic revenue and EPS guidance (EPS range ~5.620–5.660), which was neither a downside shock nor a strong upside catalyst; investors are parsing precision of margins and timing of improvement. Medtronic Reaffirms 2026 Outlook As Heart and Diabetes Units Drive Growth
• Neutral Sentiment: Technicals/analyst outlook — Technical analysts and MarketBeat highlight a “textbook” reversal and institutional accumulation that imply upside targets in the $118–$125 range; this is supportive longer term but doesn’t offset near‑term margin concerns. Medtronic’s “Textbook” Reversal: How High Can It Really Go in 2026?
• Negative Sentiment: Margin pressures and costs — Investors reacted to margin contraction (tariffs, higher costs, and investments) and reports that GAAP profit fell despite higher revenue; these near‑term profitability headwinds help explain the stock decline. Medtronic Profit Falls Despite Higher Revenue

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Morgan Stanley increased their price target on Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a research report on Wednesday, November 19th. Barclays initiated coverage on shares of Medtronic in a research note on Friday, February 13th. They set an “overweight” rating and a $116.00 target price on the stock. Royal Bank Of Canada lifted their price target on shares of Medtronic from $111.00 to $118.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 19th. TD Cowen reiterated a “buy” rating on shares of Medtronic in a report on Friday, November 14th. Finally, Citigroup started coverage on shares of Medtronic in a report on Tuesday, February 3rd. They issued a “buy” rating and a $117.00 price objective on the stock. Sixteen research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $111.21.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).